Reuters logo
BRIEF-AstraZeneca says U.S. FDA approves lung cancer drug
July 14, 2015 / 6:23 AM / 2 years ago

BRIEF-AstraZeneca says U.S. FDA approves lung cancer drug

July 14 (Reuters) - Astrazeneca Plc

* Iressa approved by U.S. FDA

* U.S. food and drug administration has approved iressa (gefitinib) tablets, 250mg once daily, for first-line treatment of patients with metastatic non-small cell lung cancer

* Astrazeneca has partnered with qiagen to provide therascreen  egfr companion diagnostic test for iressa in us

* FDA approval of Iressa is based on data from phase iv ifum 1 (iressa follow-up measure) study, assessing Iressa as a first-line treatment

* Also studying Iressa in combination with other investigational medicines, including company’s anti-pd-l1 monoclonal antibody Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below